Effectiveness of Influenza A Vaccine May Be Diminished in Patients With MPNs
Researchers report on status of immune response to influenza A vaccination, particularly memory cell clusters, in patients with myeloproliferative neoplasms.
Diagnosis & Disease Information
More Support for Influenza Vaccination in Patients With Cancer Receiving Immune Checkpoint Inhibitor Therapy
Practical implications of this study include the importance of encouraging patients with cancer considering ICI therapy to undergo influenza vaccination.
Seasonal Influenza Vaccine Safe in Patients Receiving Immunotherapy
A retrospective study sought to determine if incidence or severity of irAEs was affected by the seasonal influenza vaccine in patients undergoing immunotherapy.
Flu, Pneumonia Vaccination Rates in Cancer Patients Improved With Nurse-Driven Protocol
A nurse-drive protocol tackled the influenza and pneumococcal vaccine uptake rates at an NCI-designated comprehensive cancer center, according to a presentation at 2018 ONS Annual Congress.
Influenza Vaccination Increases Toxicity in PD-1/PD-L1 Immunotherapy Blockade for Lung Cancer
Seasonal influenza vaccination was associated with increased rates of immunologic toxicity in patients with lung cancer receiving PD-1/PD-L1 immunotherapy blockade.
Oseltamivir reduces duration and complications of influenza
Oseltamivir decreases duration of influenza symptoms by about 1 day and decreases possible respiratory infections by 44%.
Flu vaccine only 23 percent effective this season
The CDC issued a report that supports earlier findings, stating that the efficacy of this year’s flu vaccine is low.
Flu vaccine unaffected by virus mutations on the horizon
Researchers associated with the Mount Sinai Health System believe that a universal flu vaccine could be closer to development.
FDA approves Rapivab for acute uncomplicated influenza
The U.S. Food and Drug Administration (FDA) has approved RAPIVAB, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza in patients 18 years and older.
FDA approves first quadrivalent intradermal influenza vaccine
The FDA has approved Fluzone Intradermal Quadrivalent vaccine for influenza.
- Loading...
Loading...
Next post in Headlines
Loading... 
Loading...